Harrow, Inc. · NASDAQ:HROW
Harrow — Q3 2026 Earnings Presentation
30 slides from Harrow's earnings presentation, Nov 9, 2026
Slide 1: Corporate Presentation November 2026
Corporate Presentation November 2026
Slide 2: Safe Harbor
2 Corporate Presentation | November 2026 Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations
Slide 3: Harrow. We Are Ophthalmic Pharma.
3 Corporate Presentation | November 2026 Diversified provider of ophthalmic disease management solutions in North America Harrow. We Are Ophthalmic Pharma. Largest U.S. Portfolio of Prescription Ophthalmic Products Multiple Growth Drivers Across Large Ophthalmic Markets Scalable Commercial Platform
Slide 4: Investment Highlights
4 Corporate Presentation | November 2026 Investment Highlights Multiple growth drivers, a scalable commercial platform, and a new product every year Q3 YOY DEMAND GROWTH 1 Early-Stage Growth, Durable Franchises Major growth drivers remain early in their adoption curves, addressing large markets with
Slide 5: Durable Growth: A New Product Every Year
5 Corporate Presentation | November 2026 Durable Growth: A New Product Every Year At least one new product every year through the end of the decade, launched within Harrow’s existing cost structure and commercial footprint 2026 LAUNCHED / ACQUIRED BYOOVIZ ranibizumab-nuna Anti-VEGF biosimilar Launch
Slide 6: Financials & Outlook
6 Corporate Presentation | November 2026 Financials & Outlook 3Q26 | Results and Outlook Key Financial Metrics and Revenue Conversion
Slide 7: Key Financial Metrics
7 Corporate Presentation | November 2026 Key Financial Metrics FIVE-YEAR TRACK RECORD CONSOLIDATED REVENUE $ in millions 41% 5-Yr CAGR (2020–2025) $72.5M $88.6M $130.2M $199.6M $272.3M $357.5M $0M $100M $200M $300M $400M 2021 2022 2023 2024 2025 2026E Q3 2026 KEY METRICS REVENUE BRANDED REVENUE $99.
Slide 8: Q4 Bridge: Path to FY2026 Guidance
8 Corporate Presentation | November 2026 Q4 Bridge: Path to FY2026 Guidance Q4 implied by reaffirmed guidance, driven by new revenue sources, seasonal strength and product momentum Q3 TO IMPLIED Q4 REVENUE · $ IN MILLIONS $99.3M +$36.5 – $51.5M $135.8 – $150.8M Q3 2026 actual revenue Q4 growth drive
Slide 9: Four Focused Selling Teams
9 Corporate Presentation | November 2026 Four Focused Selling Teams Each team built around a common set of prescribers, care setting, and purchasing and reimbursement dynamics Access+ Dedicated to compounded products WORKS ALONGSIDE ALL THREE BRANDED TEAMS Supports Ocular Surface Disease, Retina, an
Slide 10: Ocular Surface Disease
10 Corporate Presentation | November 2026 Ocular Surface Disease VEVYE | TYRVAYA | FRESHKOTE PF | FLAREX | VERKAZIA | ZERVIATE | NATACYN
Slide 11: Ocular Surface Disease Portfolio
11 Corporate Presentation | November 2026 Cyclosporine ophthalmic solution 0.1%; water-free WATER-FREE CYCLOSPORINE Varenicline solution nasal spray 0.03 mg NASAL TEAR STIMULATION Preservative-free lubricant eye drops OTC LUBRICANT Fluorometholone acetate ophthalmic suspension 0.1% CORTICOSTEROID Cy
Slide 12: VEVYE: Best-in-Class for DED
12 Corporate Presentation | November 2026 VEVYE: Best-in-Class for DED ~22x More cyclosporine delivered into the cornea vs. Restasis Preclinical ex-vivo corneal penetration study data Rapid Onset Fastest-working immunomodulator for DED Durable Effect Significant staining improvement by Day 15, susta
Slide 13: VEVYE Q3 2026 Key Metrics
13 Corporate Presentation | November 2026 VEVYE Q3 2026 Key Metrics +83% TRx Growth Q3 ’26 vs. Q3 ’25 +17% TRx Growth Q3 ’26 vs. Q2 ’26 Quarterly Revenue U.S. net revenue | Q3 ’25 → Q3 ’26 $22.6M $25.9M $20.9M $29.4M $39.7M $M $5M $10M $15M $20M $25M $30M $35M $40M $45M Q3 2025 Q4 2025 Q1 2026 Q2 20
Slide 14: TYRVAYA: Integrated and Off to a Strong Start
14 Corporate Presentation | November 2026 TYRVAYA: Integrated and Off to a Strong Start The only FDA-approved nasal spray for dry eye disease, now part of our Ocular Surface team alongside VEVYE • 2 bottles = 30-day supply • 60 sprays per bottle (4.2 mL each) • 0.03 mg varenicline solution ZERO … Co
Slide 15: The VERKAZIA Opportunity
15 Corporate Presentation | November 2026 The VERKAZIA® Opportunity VKC is a chronic allergic eye disease — driven by immune dysregulation, across a spectrum (from highly underdiagnosed mild cases to severe and sight-threatening cases), which primarily affects children, but can reach into adulthood
Slide 16: The NATACYN Opportunity
16 Corporate Presentation | November 2026 The NATACYN® Opportunity Blepharitis is not a single infection — it is a microbiome imbalance (or dysbiosis) of the eyelid margin, driven by multiple etiologic pathogens THE ETIOLOGIC TRIAD BACTERIA Staphylococcus — lipases, toxins, biofilms DEMODEX MITES Me
Slide 17: Retina
17 Corporate Presentation | November 2026 Retina IHEEZO | BYOOVIZ | OPUVIZ IOPIDINE | TRIESENCE | VIGAMOX
Slide 18: Retina Portfolio
18 Corporate Presentation | November 2026 Chloroprocaine HCl ophthalmic gel 3% OCULAR ANESTHETIC Ranibizumab-nuna; LUCENTIS® biosimilar ANTI-VEGF BIOSIMILAR Aflibercept-yszy; EYLEA® biosimilar, launching 2027 ANTI-VEGF BIOSIMILAR Apraclonidine ophthalmic solution 1% INTRAOCULAR PRESSURE CONTROL Tria
Slide 19: IHEEZO Overview
19 Corporate Presentation | November 2026 IHEEZO Overview See References, slide 30 First-in-Class First approved use of chloroprocaine in the US ophthalmic market Large TAM ~14M+ annual U.S. ocular procedures require surface anesthesia Reimbursement Permanent J-code (J2403) in the in-office setting
Slide 20: IHEEZO Total Addressable Market
20 Corporate Presentation | November 2026 IHEEZO Total Addressable Market ~14M+ All eight procedure categories are IHEEZO-applicable | CPT codes shown with each procedure Estimated Annual U.S. In-Office Procedures | Standard of Care Requires Ocular Surface Anesthesia 0.2M 0.3M 0.3M 0.5M 0.7M 1.0M 1.
Slide 21: IHEEZO Q3 2026 Key Metrics
21 Corporate Presentation | November 2026 IHEEZO Q3 2026 Key Metrics 62,210 Customer Unit Demand* Q3 ’26; 5% below record Q2 ’26 +21% Unit Demand Growth Q3 ’26 vs. Q3 ’25 +62% Sequential Revenue Growth Q3 ’26 vs. Q2 ’26 Q4 Historically Strongest Quarter Seasonal demand Quarterly Customer Unit Demand
Slide 22: IHEEZO QUELL Phase 4 Topline Results
22 Corporate Presentation | November 2026 IHEEZO QUELL Phase 4 Topline Results Study Design Evaluating a topical gel against an anesthetic regimen that includes a highly potent injection Key Findings See References, slide 30 Pain scores are patient-reported; lower scores indicate less pain. Primary
Slide 23: Surgical
23 Corporate Presentation | November 2026 Surgical TRIESENCE | MAXIDEX | NEVANAC | ILEVRO TOBRADEX ST | MAXITROL | VIGAMOX Pipeline: G-MELT | YOCHIL | Next-Gen TRIESENCE (H-N08)
Slide 24: Surgical Portfolio
24 Corporate Presentation | November 2026 Triamcinolone acetonide injectable suspension 40 mg/mL Also sold by the Retina team CORTICOSTEROID Dexamethasone ophthalmic suspension 0.1% CORTICOSTEROID Nepafenac ophthalmic suspension 0.1% NSAID Nepafenac ophthalmic suspension 0.3% NSAID Tobramycin / dexa
Slide 25: TRIESENCE Overview
25 Corporate Presentation | November 2026 TRIESENCE Overview Injectable suspension (triamcinolone acetonide 40 mg/mL) with separate reimbursement in every traditional care setting Regulatory Only FDA-approved preservative-free synthetic corticosteroid for injectable ophthalmic use Supply 5-year supp
Slide 26: TRIESENCE Q3 2026 Key Metrics
26 Corporate Presentation | November 2026 TRIESENCE Q3 2026 Key Metrics See References, slide 30 20,022 Customer Unit Demand* Strongest quarter under Harrow $10.7M Revenue Record quarterly revenue +37% Sequential Unit Growth Q3 ’26 vs. Q2 ’26 +110% Unit Demand Growth Q3 ’26 vs. Q3 ’25 Quarterly Unit
Slide 27: G-MELT: IV & Opioid-Free Sedation
27 Corporate Presentation | November 2026 G-MELT: IV & Opioid-Free Sedation Fixed-dose sublingual tablet combining 3 mg midazolam + 50 mg ketamine (non-opioid) WHAT MAKES G-MELT DIFFERENT Zydis® sublingual technology Dissolves in seconds under the tongue. Exclusive license from Catalent; Zydis® has
Slide 28: YOCHIL: Pediatric Oral Midazolam ODT
28 Corporate Presentation | November 2026 YOCHIL: Pediatric Oral Midazolam ODT Oral dissolving tablet delivering midazolam for sedation, anxiolysis, and amnesia prior to diagnostic, therapeutic, or endoscopic procedures in pediatric patients WHAT MAKES YOCHIL DIFFERENT De-risked clinical pathway Ext
Slide 29: Upcoming Catalysts: Key Milestones Through 2027
29 Corporate Presentation | November 2026 Upcoming Catalysts: Key Milestones Through 2027 Regulatory, clinical, commercial and corporate events expected between now and the end of 2027 Q4 2026 G-MELT NDA submission Filing for sublingual cataract-surgery sedation, moved ahead of the 1H 2027 plan Expe
Slide 30: References
30 Corporate Presentation | November 2026 References Sources and footnotes for figures cited throughout this presentation Data sources Market, prescription, and procedure data are drawn from IQVIA (including Xponent), PhilRx, Vestrum Health, Market Scope, Definitive Healthcare, the AAO IRIS Registry